Kesler Norman & Wride LLC Has $880,000 Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Kesler Norman & Wride LLC increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 66.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,776 shares of the medical equipment provider's stock after purchasing an additional 707 shares during the quarter. Kesler Norman & Wride LLC's holdings in Intuitive Surgical were worth $880,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of ISRG. Norges Bank acquired a new stake in Intuitive Surgical during the 4th quarter worth $2,401,493,000. GAMMA Investing LLC grew its holdings in shares of Intuitive Surgical by 54,010.7% in the 1st quarter. GAMMA Investing LLC now owns 3,028,576 shares of the medical equipment provider's stock valued at $14,999,630,000 after buying an additional 3,022,979 shares during the period. Capital Research Global Investors raised its stake in Intuitive Surgical by 25.5% during the 4th quarter. Capital Research Global Investors now owns 3,381,302 shares of the medical equipment provider's stock worth $1,764,904,000 after buying an additional 687,906 shares during the period. Northern Trust Corp raised its stake in Intuitive Surgical by 15.8% during the 4th quarter. Northern Trust Corp now owns 3,619,293 shares of the medical equipment provider's stock worth $1,889,126,000 after buying an additional 494,496 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Intuitive Surgical by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 32,212,196 shares of the medical equipment provider's stock worth $16,813,478,000 after acquiring an additional 360,591 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Intuitive Surgical news, SVP Mark Brosius sold 216 shares of Intuitive Surgical stock in a transaction on Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the transaction, the senior vice president directly owned 907 shares of the company's stock, valued at $510,740.77. The trade was a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Robert Desantis sold 188 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $515.91, for a total transaction of $96,991.08. Following the sale, the executive vice president owned 5,224 shares of the company's stock, valued at approximately $2,695,113.84. This represents a 3.47% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,998 shares of company stock worth $2,611,577 in the last quarter. Insiders own 0.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ISRG. Citigroup reaffirmed a "buy" rating and set a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Evercore ISI raised their target price on shares of Intuitive Surgical from $470.00 to $550.00 and gave the stock an "in-line" rating in a report on Tuesday. Barclays reduced their price target on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Robert W. Baird dropped their price objective on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Finally, Truist Financial cut their price objective on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat, Intuitive Surgical currently has an average rating of "Moderate Buy" and a consensus price target of $592.59.

Intuitive Surgical Price Performance

Shares of ISRG opened at $526.05 on Friday. The company has a market cap of $188.55 billion, a PE ratio of 77.13, a price-to-earnings-growth ratio of 5.60 and a beta of 1.64. The firm has a 50-day moving average of $538.20 and a 200-day moving average of $536.86. Intuitive Surgical, Inc. has a one year low of $413.82 and a one year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. The business had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. During the same quarter last year, the company posted $1.50 earnings per share. Analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.